title: Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.
abstract: Partial agonist therapies rely variously on two hypotheses: the partial agonists have their effects through chronic low-level receptor activation or the partial agonists work by decreasing the effects of endogenous or exogenous full agonists. The relative significance of these activities probably depends on whether acute or chronic effects are considered. We studied nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus laevis oocytes to test a model for the acute interactions between acetylcholine (ACh) and weak partial agonists. Data were best-fit to a basic competition model that included an additional factor for noncompetitive inhibition. Partial agonist effects were compared with the nAChR antagonist bupropion in prolonged bath application experiments that were designed to mimic prolonged drug exposure typical of therapeutic drug delivery. A primary effect of prolonged application of nicotine was to decrease the response of all nAChR subtypes to acute applications of ACh. In addition, nicotine, cytisine, and varenicline produced detectable steady-state activation of α4β2* [(α4)(2)(β2)(3), (α4)(3)(β2)(2), and (α4)(2)(β2)(2)α5)] receptor subtypes that was not seen with other test compounds. Partial agonists produced no detectable steady-state activation of α7 nAChR, but seemed to show small potentiation of ACh-evoked responses; however, "run-up" of α7 ACh responses was also sometimes observed under control conditions. Potential off-target effects of the partial agonists therefore included the modulation of α7 responses by α4β2 partial agonists and decreases in α4β2* responses by α7-selective agonists. These data indicate the dual effects expected for α4β2* partial agonists and provide models and insights for utility of partial agonists in therapeutic development.
authors.affiliation: Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL 32610-0267, USA. rlpapke@ufl.edu
authors.forename: Roger L
authors.initials: RL
authors.lastname: Papke
authors.forename: Caryn
authors.initials: C
authors.lastname: Trocmé-Thibierge
authors.forename: Daniela
authors.initials: D
authors.lastname: Guendisch
authors.forename: Shehd Abdullah Abbas
authors.initials: SA
authors.lastname: Al Rubaiy
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Bloom
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D001392:Azocines / Q000494:pharmacology; D001552:Benzazepines / Q000494:pharmacology; D016642:Bupropion / Q000494:pharmacology; D018076:DNA, Complementary / Q000096:biosynthesis / Q000235:genetics; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D055724:Electrophysiological Phenomena; D006801:Humans; D009538:Nicotine / Q000494:pharmacology; D018722:Nicotinic Agonists / Q000494:pharmacology*; D018733:Nicotinic Antagonists / Q000494:pharmacology; D009865:Oocytes / Q000378:metabolism; D011726:Pyridinium Compounds / Q000494:pharmacology; D011807:Quinolizines / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D011978:Receptors, Nicotinic / Q000187:drug effects*; D016540:Smoking Cessation; D000068580:Varenicline; D014981:Xenopus; D064569:alpha7 Nicotinic Acetylcholine Receptor; D000093843:Quinolizidine Alkaloids
chemical_list: D000109:Acetylcholine; D000470:Alkaloids; D001392:Azocines; D001552:Benzazepines; D016642:Bupropion; D018076:DNA, Complementary; D018765:Dopamine Uptake Inhibitors; D009538:Nicotine; D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; D011726:Pyridinium Compounds; D011807:Quinolizines; D011810:Quinoxalines; D011978:Receptors, Nicotinic; D000068580:Varenicline; D064569:alpha7 Nicotinic Acetylcholine Receptor; C579167:Chrna7 protein, human; C524163:S 24795; C403531:nicotinic receptor alpha4beta2; C004712:cytisine; D000093843:Quinolizidine Alkaloids